Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
about
Acute renal injury after partial hepatectomyDo vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysisEffects of paracentesis on hemodynamic parameters and respiratory function in critically ill patientsPrevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal.Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.Acute abdomen secondary to incarcerated umbilical hernia after treatment of massive cirrhotic ascites.Management of cirrhotic ascitesTIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysisAcute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions.Hypoalbuminemia.Nutrition assessment and management in advanced liver disease.Acute kidney injury and hepatorenal syndrome in cirrhosis.Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.Renal dysfunction in cirrhosis is not just a vasomotor nephropathy.Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system.Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement.Albumin in chronic liver disease: structure, functions and therapeutic implications.Diastolic dysfunction in cirrhosis.Concentrated ascites reinfusion therapy for sinusoidal obstructive syndrome after hematopoietic stem cell transplantation.Ascites, refractory ascites and hyponatremia in cirrhosis.NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis.Clinical Features of Refractory Ascites in Outpatients.Automated low flow pump system for the treatment of refractory ascites: a single-center experience.Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report.The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX (©) Catheter.Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.Interactions between virus-related factors and post-transplant ascites in patients with hepatitis C and no cirrhosis: role of cryoglobulinemia.Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis.Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?Management of refractory cirrhotic ascites: challenges and solutions
P2860
Q26740331-CE273B16-3C89-4756-8EEA-B763EA63376DQ26778032-EA92FDAC-2226-4538-AFEA-6B404F17015DQ27009006-710AA0B0-D036-4B68-9528-2156F37D41CEQ31148915-5039F2A1-2AAC-4E45-B083-951CAED46F43Q33905612-B180B4DD-F15C-4907-9A8A-4BD5F81562EAQ34077523-DF08FEC6-1D45-4677-BC1A-5EC95C1DABF6Q34399128-47C97DC0-5618-44EE-8A44-35A51D277DAEQ34475601-DC986123-4C94-4B83-9E27-D0DE61F9DD12Q35120398-F9A49FB1-6DC8-4051-A4A1-015D4D84DD80Q37903856-11173D50-32D3-4D53-AE21-A285BD7EBFAAQ38052843-3BF5BBC2-CAEE-40BB-927A-4FD708E7C68AQ38074112-89C58D3E-3A05-4D8F-8C77-89166D353E69Q38243669-82EC94E7-44A2-4B8F-B800-05A32F480559Q38244333-65FCC0D9-F447-4656-8D5D-5A0578075934Q38258146-769C0860-26C5-415C-B275-FE323800BFDDQ38263192-28FCFC71-63E3-43E9-9A24-5CAE8C34CE35Q38417924-F248CE61-85FA-4FC3-8F0C-6B7494233F25Q38595462-80D85FAA-8603-428C-889A-850608615FA0Q38881630-F713B453-0C2B-4263-BB05-FC83A6469264Q39227021-DEEA4B60-F044-4356-B938-E69990B43588Q39323841-41896D2D-8957-4820-BC0B-0AEF3ADD2F71Q39660987-476F1EC8-94D7-4FA0-A4A3-08D013F9ABF7Q40100282-E45A8084-7FF9-44F1-84E6-4EB349AECAD8Q40322777-D6620FC1-7F9E-4B53-8267-FCB0B49F4119Q40496089-C09360B7-DD86-4DAB-BC63-43F0BFE57E4CQ40603838-F04774F5-6B2A-4200-8FD8-11D11C8463F0Q40816326-64656021-F933-4DBF-9F32-686A0ED9D828Q41722162-B438FD21-F714-4E61-95C3-B9BA85117D8DQ47280183-CA60142A-400C-4EDE-8F90-2A117C36DB31Q48331734-CD7153FF-F81F-4561-A289-A4C9F11E5898Q51243082-8A9927FD-FEE4-4507-B484-55494D404CC2Q57407557-250255EC-5952-4B46-9F56-3DEB5528209A
P2860
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Refractory ascites: pathogenes ...... on in patients with cirrhosis.
@en
Refractory ascites: pathogenes ...... on in patients with cirrhosis.
@nl
type
label
Refractory ascites: pathogenes ...... on in patients with cirrhosis.
@en
Refractory ascites: pathogenes ...... on in patients with cirrhosis.
@nl
prefLabel
Refractory ascites: pathogenes ...... on in patients with cirrhosis.
@en
Refractory ascites: pathogenes ...... on in patients with cirrhosis.
@nl
P2093
P2860
P1433
P1476
Refractory ascites: pathogenes ...... on in patients with cirrhosis.
@en
P2093
Florence Wong
Francesco Salerno
Guadalupe Garcia-Tsao
Mauro Bernardi
Monica Guevara
Paolo Angeli
Samuel S Lee
P2860
P304
P356
10.1111/J.1478-3231.2010.02272.X
P577
2010-05-21T00:00:00Z